EUVIMEDEUVIMED entdecken
Open Access

Design of a multi‐epitope‐based vaccine consisted of immunodominant epitopes of structural proteins of SARS‐CoV‐2 using immunoinformatics approach

Shahab Mahmoudvand iD, Hadi Esmaeili Gouvarchin Ghaleh, Farid Azizi Jalilian, Mahdieh Farzanehpour, Ruhollah Dorostkar iD

Biotechnology and Applied Biochemistry · 2023

DOI: 10.1002/bab.2431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2023. Verfasst von Shahab Mahmoudvand und 4 weiteren Autor:innen. Beteiligte Einrichtung: Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has shown rapid global spread and has resulted in a significant death toll worldwide. In this study, we aimed to design a multi‐epitope vaccine against SARS‐CoV‐2 based on structural proteins S, M, N, and E. We identified B‐ and T‐cell epitopes and then the antigenicity, toxicity, allergenicity, and similarity of predicted epitopes were analyzed. T‐cell epitopes were docked with corresponding HLA alleles. Consequently, the selected T‐ and B‐cell epitopes were included in the final construct. All selected epitopes were connected with different linkers and flagellin and pan‐HLA DR binding epitopes (PADRE) as an adjuvant were used in the vaccine construct. Furthermore, molecular docking was used to evaluate the complex between the final vaccine construct and two alleles, HLA‐A*02:01 and HLA‐DRB1*01:01. Finally, codons were optimized for in silico cloning into pET28a(+) vector using SnapGene. The final vaccine construct comprised 11 CTL, HTL, and B‐cell epitopes corresponding to 394 amino acid residues. In silico evaluation showed that the designed vaccine might potentially promote an immune response. Further in vivo preclinical and clinical testing is required to determine the safety and efficacy of the designed vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansImmunodominant EpitopesEpitopes, T-LymphocyteEpitopes, B-LymphocyteCOVID-19 VaccinesMolecular Docking SimulationComputational Biology

Stichwörter der Autor:innen

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)multi-epitope vaccinestructural proteins

Substanzen

Immunodominant EpitopesEpitopes, T-LymphocyteEpitopes, B-LymphocyteCOVID-19 Vaccines

Autor:innen und Institutionen

  • Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Department of Medical Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

ORCID-Profile: Shahab Mahmoudvand, Ruhollah Dorostkar

Zitieren

APA

Mahmoudvand, S., Esmaeili Gouvarchin Ghaleh, H., Jalilian, F. A., Farzanehpour, M., & Dorostkar, R. (2023). Design of a multi‐epitope‐based vaccine consisted of immunodominant epitopes of structural proteins of SARS‐CoV‐2 using immunoinformatics approach. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2431

Vancouver

Mahmoudvand S, Esmaeili Gouvarchin Ghaleh H, Jalilian FA, Farzanehpour M, Dorostkar R. Design of a multi‐epitope‐based vaccine consisted of immunodominant epitopes of structural proteins of SARS‐CoV‐2 using immunoinformatics approach. Biotechnology and Applied Biochemistry. 2023. doi:10.1002/bab.2431

BibTeX
@article{Mahmoudvand2023,
  author = {Mahmoudvand, Shahab and Esmaeili Gouvarchin Ghaleh, Hadi and Jalilian, Farid Azizi and Farzanehpour, Mahdieh and Dorostkar, Ruhollah},
  title = {Design of a multi‐epitope‐based vaccine consisted of immunodominant epitopes of structural proteins of SARS‐CoV‐2 using immunoinformatics approach},
  journal = {Biotechnology and Applied Biochemistry},
  year = {2023},
  doi = {10.1002/bab.2431}
}
Kostenlos starten →